• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Quotient Limited Announces Appointment of Chief Financial Officer

    10/12/21 8:45:00 AM ET
    $DGX
    $QTNT
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $DGX alert in real time by email

    JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end.

    "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I worked with Ali at Quest and was impressed by his compelling track record of driving results and building a global finance organization. With Ali's appointment, we have a strong management team in place to continue to drive revenue growth and the successful execution of our corporate strategy. I would also like to thank Peter for his ongoing commitment and dedication to Quotient," said Manuel O. Méndez, Chief Executive Officer of Quotient. 

    Ali joins the Company from Quest Diagnostics (NYSE:DGX), where he most recently served as Vice President, Finance supporting the Commercial organization. Over a 12-year career at Quest, Ali has assumed finance positions of increasing responsibility supporting Quest's strategy around Hospitals, Health Plans, Global Markets, Oncology and Anatomic Pathology, Professional Lab Services and Clinical Trials.

    Ali started his career as a financial analyst with General Motors (GM) in 1997. He moved to GM Treasurer's Office in roles in the US and Europe covering capital markets, corporate strategy, capital planning, mergers and acquisitions, pension and healthcare funding, and investor relations. 

    Ali holds an MBA in Finance from The Wharton School at the University of Pennsylvania and a BS in Finance from Duquesne University.

    "I am very excited and honored to join Quotient at this important phase of the company's journey to transform transfusion diagnostics and beyond. I look forward to bringing my experience in global finance and operations to execute on our strategy and deliver value to shareholders," said Mr. Kiboro. 

    About Quotient Limited

    Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

    CONTACT: Investor Relations, [email protected]; +41 22 545 52 26



    Primary Logo

    Get the next $DGX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX
    $QTNT

    CompanyDatePrice TargetRatingAnalyst
    Quest Diagnostics Incorporated
    $DGX
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    Quest Diagnostics Incorporated
    $DGX
    4/2/2025$195.00Buy
    Redburn Atlantic
    Quest Diagnostics Incorporated
    $DGX
    3/4/2025$185.00Buy → Neutral
    Citigroup
    Quest Diagnostics Incorporated
    $DGX
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    Quest Diagnostics Incorporated
    $DGX
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    Quest Diagnostics Incorporated
    $DGX
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    Quest Diagnostics Incorporated
    $DGX
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    Quest Diagnostics Incorporated
    $DGX
    8/28/2024$165.00In-line
    Evercore ISI
    More analyst ratings

    $DGX
    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Prevoznik Michael E exercised 227 shares at a strike of $103.57 and sold $42,706 worth of shares (227 units at $188.13) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    9/30/25 4:36:58 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP & General Counsel Prevoznik Michael E exercised 28,463 shares at a strike of $103.57 and sold $5,326,042 worth of shares (28,463 units at $187.12) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    9/25/25 4:39:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $365,375 worth of shares (1,975 units at $185.00), decreasing direct ownership by 11% to 15,269 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/25/25 4:27:59 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $QTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DGX
    $QTNT
    SEC Filings

    View All

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company's curated Advanced Labs panel, which tests an extensive set of biomarkers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/WHOOP Launches Clinician-Reviewed Advanced Labs, Unlockin

    9/30/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/26/25 4:12:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/23/25 4:14:25 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/21/25 12:10:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $QTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

    Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

    10/26/22 7:05:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $DGX
    $QTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13D filed by Quotient Limited

    SC 13D - Quotient Ltd (0001596946) (Subject)

    2/27/23 4:14:00 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $DGX
    $QTNT
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

    7/22/25 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care